Breaking News Instant updates and real-time market news.

INGN

Inogen

$137.39

3.57 (2.67%)

09:08
04/13/18
04/13
09:08
04/13/18
09:08

Inogen data breach won't be big issue for sales, says Piper Jaffray

Piper Jaffray analyst JP McKim believes the data security breach disclosed this morning by Inogen won't be a big issue from a revenue perspective but likely may result in additional spending to ensure it will not occur again. In aggregate, the analyst views this morning's regulatory filing as a "net positive for the stock" since the company also said it expects to deliver a "strong" Q1 results and is confident in its full year revenue outlook. Inogen is positioned for another beat-and-raise quarter in a few weeks, McKim tells investors in a research note. He keeps an Overweight rating on the shares with a $145 price target.

  • 19

    Apr

  • 06

    Jun

  • 07

    Jun

  • 12

    Jun

INGN Inogen
$137.39

3.57 (2.67%)

04/02/18
PIPR
04/02/18
NO CHANGE
PIPR
Overweight
Piper remains buyer of Inogen with Mobi a no-show at conference
Piper Jaffray analyst JP McKim says that while we did not attend Med Trade conference in Vegas late last week, he heard from some who did attend that there was no sign of ResMed's (RMD) Mobi at the conference and reps said there is no official launch date on the calendar. He believes that ResMed either chose not to showcase Mobi at Med Trade or there is a delay in the launch. McKim believes that ultimately Inogen (INGN) "will continue to have the best technology and innovation engine." He adds that less competition is always a good thing. The analyst remains a buyer of Inogen.
02/28/18
NEED
02/28/18
NO CHANGE
Target $150
NEED
Strong Buy
Inogen price target raised to $150 from $125 at Needham
Needham analyst Mike Matson raised his price target on Inogen to $150 after the company's Q4 earnings beat and raised FY18 outlook. Matson notes that the revenue upside came from both domestic B2B and direct to consumer offerings, which both grew by over 35%, though margins declined on higher SG&A expenses. Matson keeps his Strong Buy rating, forecasting sales force expansion and Medicare reimbursement to produce even faster DTC growth this year.
02/20/18
PIPR
02/20/18
UPGRADE
PIPR
Overweight
Inogen upgraded to Overweight from Neutral at Piper Jaffray
Piper Jaffray analyst JP McKim upgraded Inogen (INGN) to Overweight and raised his price target for the shares to $137 from $96. The analyst also keeps an Overweight rating on Tactile Systems (TCMD) with a $36 price target. McKim, who just took over coverage of both names, believes the companies "have disruptive business models in going direct to consumer" in an "ever-changing healthcare environment." Benefiting Inogen, the analyst thinks oxygen tanks will go away in 10 years.
12/22/17
NEED
12/22/17
NO CHANGE
Target $32
NEED
Strong Buy
Boston Scientific, Inogen favorite 2018 picks in med tech at Needham
Needham analyst Mike Matson expects 2018 med tech fundamentals to remain stable in 2018 and thinks the medical sector is entering 2018 on "solid footing." Matson's favorite stock and favorite large-cap pick for 2018 is Boston Scientific (BSX), and favorite small/mid-cap pick is Inogent (INGN), both of which are Strong Buy rated. The analyst thinks Boston Scientific has a strong product cycle that should allow it to outpace peers and views 2018 consensus estimates as conservative. For Inogen, Matson sees further upside from the rapid adoption of POCs by home medial equipment companies, direct-to-consumer revenue growth, and very conservative guidance.

TODAY'S FREE FLY STORIES

TBPH

Theravance Biopharma

$28.10

-0.32 (-1.13%)

, JNJ

Johnson & Johnson

$139.12

0.44 (0.32%)

15:06
10/23/18
10/23
15:06
10/23/18
15:06
Recommendations
Theravance Biopharma, Johnson & Johnson analyst commentary  »

Piper says Theravance…

TBPH

Theravance Biopharma

$28.10

-0.32 (-1.13%)

JNJ

Johnson & Johnson

$139.12

0.44 (0.32%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 28

    Oct

  • 13

    Nov

  • 27

    Nov

  • 18

    Dec

15:05
10/23/18
10/23
15:05
10/23/18
15:05
General news
More from Bostic and Kaplan: Bostic favors raising rates four times this year »

More from Bostic and…

RRC

Range Resources

$16.52

-0.18 (-1.08%)

15:04
10/23/18
10/23
15:04
10/23/18
15:04
Options
Range Resources options imply 8.1% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

BTC

Bitcoin

$0.00

(0.00%)

, BITCOIN

Bitcoin

$0.00

(0.00%)

15:01
10/23/18
10/23
15:01
10/23/18
15:01
Hot Stocks
NY DFS authorizes Coinbase Global to form Coinbase Custody Trust Company »

New York Financial…

BTC

Bitcoin

$0.00

(0.00%)

BITCOIN

Bitcoin

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WFC

Wells Fargo

$51.59

-0.05 (-0.10%)

15:01
10/23/18
10/23
15:01
10/23/18
15:01
Hot Stocks
Wells Fargo raises share repurchase authority by 350M shares »

The Wells Fargo board of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Apr

  • 13

    Jul

  • 12

    Oct

HLT

Hilton

$69.20

-0.97 (-1.38%)

15:00
10/23/18
10/23
15:00
10/23/18
15:00
Options
Hilton options see continued interest ahead of earnings »

Hilton options see…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 24

    Oct

15:00
10/23/18
10/23
15:00
10/23/18
15:00
General news
Treasury Closing Summary: »

Treasury Closing Summary:…

TSLA

Tesla

$292.51

31.48 (12.06%)

14:55
10/23/18
10/23
14:55
10/23/18
14:55
Hot Stocks
Citron's Left says would be 'wrong' to be short Tesla ahead of Q3 report »

Citron Research's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

  • 29

    Oct

  • 13

    Dec

IBTX

Independent Bank

$57.55

1.08 (1.91%)

14:54
10/23/18
10/23
14:54
10/23/18
14:54
Recommendations
Independent Bank analyst commentary  »

Independent Bank price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 09

    Nov

HXL

Hexcel

14:52
10/23/18
10/23
14:52
10/23/18
14:52
Upgrade
Hexcel rating change  »

Hexcel upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

CVE

Cenovus Energy

$8.53

-0.085 (-0.99%)

14:50
10/23/18
10/23
14:50
10/23/18
14:50
Options
Afternoon call buyer in Cenovus Energy »

Afternoon call buyer in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

14:50
10/23/18
10/23
14:50
10/23/18
14:50
General news
Fed's Kaplan reiterated the FOMC should gradual reduce accommodation »

Fed's Kaplan…

TXN

Texas Instruments

$99.84

0.1 (0.10%)

14:49
10/23/18
10/23
14:49
10/23/18
14:49
Options
Texas Instruments options imply 7.3% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

BIIB

Biogen

$319.27

3.6 (1.14%)

14:47
10/23/18
10/23
14:47
10/23/18
14:47
Recommendations
Biogen analyst commentary  »

Piper a buyer of Biogen…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 24

    Oct

  • 25

    Oct

TSLA

Tesla

$292.44

31.41 (12.03%)

14:44
10/23/18
10/23
14:44
10/23/18
14:44
Hot Stocks
Musk says Tesla will cut some interior configuration options for Model S, X »

Tesla CEO Elon Musk…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

  • 29

    Oct

  • 13

    Dec

VNQ

Vanguard REIT Index Fund

$77.68

0.64 (0.83%)

14:40
10/23/18
10/23
14:40
10/23/18
14:40
Options
66K Vanguard Real Estate Fund Dec 76 - Jan 72 put spreads trade 71c »

66K Vanguard Real Estate…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VEEV

Veeva

$88.99

-2.77 (-3.02%)

14:35
10/23/18
10/23
14:35
10/23/18
14:35
Options
Veeva put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

14:35
10/23/18
10/23
14:35
10/23/18
14:35
General news
Fed Board minutes showed showed most Banks supported the September 26 rate hike »

Fed Board minutes showed…

TSLA

Tesla

$292.00

30.97 (11.86%)

14:32
10/23/18
10/23
14:32
10/23/18
14:32
Recommendations
Tesla analyst commentary  »

Tesla's moved up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

  • 29

    Oct

  • 13

    Dec

TTWO

Take-Two

$118.82

-1.69 (-1.40%)

14:30
10/23/18
10/23
14:30
10/23/18
14:30
Periodicals
'Red Dead Redemption 2' development a difficult experience, Kotaku says »

Take-Two's Rockstar…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 24

    Oct

SELB

Selecta Biosciences

$9.25

-4.12 (-30.82%)

, HZNP

Horizon Pharma

$18.49

-0.76 (-3.95%)

14:29
10/23/18
10/23
14:29
10/23/18
14:29
Recommendations
Selecta Biosciences, Horizon Pharma analyst commentary  »

Selecta SEL-212 data…

SELB

Selecta Biosciences

$9.25

-4.12 (-30.82%)

HZNP

Horizon Pharma

$18.49

-0.76 (-3.95%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 23

    Oct

  • 07

    Nov

  • 27

    Nov

BCS

Barclays

$8.60

0.11 (1.30%)

14:20
10/23/18
10/23
14:20
10/23/18
14:20
Options
8-strike put buyers in Barclays Bank ahead of earnings »

8-strike put buyers in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SELB

Selecta Biosciences

$8.93

-4.44 (-33.21%)

14:19
10/23/18
10/23
14:19
10/23/18
14:19
Recommendations
Selecta Biosciences analyst commentary  »

Selecta Biosciences…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

SLG

SL Green Realty

$92.15

0.36 (0.39%)

14:18
10/23/18
10/23
14:18
10/23/18
14:18
Downgrade
SL Green Realty rating change  »

SL Green Realty…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

14:17
10/23/18
10/23
14:17
10/23/18
14:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.